secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIMEDX GROUP, INC. (MDXG)
CIK:        0001376339
Form:       8-K
Filed at:   2024-03-27T23:59:59+00:00
Accession:  0001376339-24-000026
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA rules AXIOFILL does not qualify as HCT/P; MiMedx to sue, reiterates 2024 guidance
--------------------------------------------------------------------------------

- FDA determined AXIOFILL does not meet HCT/P criteria under Section 361, treating it as a 351 biologic product.
- MiMedx files suit in U.S. District Court for Northern District of Georgia to challenge FDA's decision.
- Company plans to continue marketing AXIOFILL while legal proceedings are ongoing.
- Reiterates 2024 guidance: low double-digit net sales growth, adjusted EBITDA margin above 20%.
- Acquired exclusive rights to bovine-derived collagen particulate from Regenity Biosciences for new product later in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1376339/000137633924000026/0001376339-24-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1376339/000137633924000026/mdxg-20240327.htm
  HTML page:      https://secwatch.observer/filing/0001376339-24-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer